Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-01-07
2009-02-03
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S210010, C514S252120, C514S415000
Reexamination Certificate
active
07485651
ABSTRACT:
Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
REFERENCES:
patent: 2126329 (1938-08-01), Hoffer
patent: 2400913 (1946-05-01), Burger
patent: 2695295 (1954-11-01), Swain
patent: 3041344 (1962-06-01), Janssen
patent: 3488352 (1970-01-01), Schipper et al.
patent: 3574839 (1971-04-01), Schipper et al.
patent: 3816433 (1974-06-01), Hernestam et al.
patent: 3912743 (1975-10-01), Christensen et al.
patent: 3925387 (1975-12-01), Maruyama et al.
patent: 3932411 (1976-01-01), Braun et al.
patent: 4031101 (1977-06-01), Fleming
patent: 4045566 (1977-08-01), Archibald et al.
patent: 4073790 (1978-02-01), Archibald et al.
patent: 4344952 (1982-08-01), Hernestam et al.
patent: 4565821 (1986-01-01), Chiou
patent: 4673790 (1987-06-01), Sawada et al.
patent: 4705795 (1987-11-01), Lafon
patent: 4992457 (1991-02-01), Schulman et al.
patent: 5093333 (1992-03-01), Saab
patent: 5175166 (1992-12-01), Dunbar et al.
patent: 5177077 (1993-01-01), Hohlweg et al.
patent: 5276035 (1994-01-01), Hohlweg et al.
patent: 5403845 (1995-04-01), Dunbar et al.
patent: 5468875 (1995-11-01), Sabb et al.
patent: 5470850 (1995-11-01), Foged et al.
patent: 5510478 (1996-04-01), Sabb
patent: 5512562 (1996-04-01), Hohlweg et al.
patent: 5534522 (1996-07-01), Ando et al.
patent: 5571819 (1996-11-01), Sabb et al.
patent: 5726179 (1998-03-01), Messer, Jr. et al.
patent: 5756501 (1998-05-01), Sabb
patent: 5834458 (1998-11-01), Mitch
patent: 6528529 (2003-03-01), Brann et al.
patent: 610830 (1962-05-01), None
patent: 2259004 (1973-06-01), None
patent: 3706585 (1988-09-01), None
patent: 42 34 198 (1994-04-01), None
patent: 4234198 (1994-04-01), None
patent: 0 332 570 (1989-09-01), None
patent: 384285 (1990-08-01), None
patent: 0 473 442 (1991-08-01), None
patent: 0 514 277 (1992-11-01), None
patent: 370415 (1993-06-01), None
patent: 647642 (1995-04-01), None
patent: 311313 (1995-05-01), None
patent: 384288 (1995-05-01), None
patent: 709381 (1996-05-01), None
patent: 723781 (1996-07-01), None
patent: 727208 (1996-08-01), None
patent: 727209 (1996-08-01), None
patent: 429344 (1996-09-01), None
patent: 0 805 153 (1997-11-01), None
patent: 805153 (1997-11-01), None
patent: 1382425 (1965-03-01), None
patent: 1543944 (1968-09-01), None
patent: 1570446 (1969-06-01), None
patent: 2261008 (1975-09-01), None
patent: 874206 (1961-08-01), None
patent: 1061571 (1967-03-01), None
patent: 1142143 (1969-02-01), None
patent: 61280497 (1986-12-01), None
patent: 6298732 (1994-10-01), None
patent: 6305967 (1994-11-01), None
patent: 6603799 (1966-09-01), None
patent: WO 93/00313 (1993-01-01), None
patent: WO 93/14089 (1993-07-01), None
patent: WO 93/18772 (1993-09-01), None
patent: WO 94/22861 (1994-10-01), None
patent: WO95/00131 (1995-01-01), None
patent: WO 95/25731 (1995-09-01), None
patent: WO 95/31457 (1995-11-01), None
patent: 96/02250 (1996-02-01), None
patent: WO 96/03377 (1996-02-01), None
patent: WO 96/19479 (1996-06-01), None
patent: WO 96/26196 (1996-08-01), None
patent: WO 96/38422 (1996-12-01), None
patent: WO 96/40687 (1996-12-01), None
patent: WO 97/00894 (1997-01-01), None
patent: WO 97/40044 (1997-10-01), None
patent: WO 97/40045 (1997-10-01), None
patent: WO 98/00412 (1998-01-01), None
patent: WO 98/05292 (1998-02-01), None
patent: WO 98/06697 (1998-02-01), None
patent: WO 98/47900 (1998-10-01), None
patent: WO 99/17771 (1999-04-01), None
patent: WO 99/50247 (1999-10-01), None
Ogawa et al., Chemical Abstracts, vol. 103, No. 116074 (1985).
Aktiebolog Ferrosan, Chemical Abstracts 66:37775v (1967).
Albrecht et al., Chemical Abstracts 110:114683 (1989).
Aldous, F.A.B., Structure-Activity Relationships in Psychotomimetic Phenylalkylamines. J. Med. Chem. 17:1100-1111 (1974).
Avery et al., Potential Role of Muscarinic Agonists in Alzheimer's Disease. Drugs & Aging 11(6):450-459 (1997).
Bailey et al., Piperidine derivatives. VIII. Substituted Piperdino-alkyl benzoates, pp. 1633-1640 (1930).
Bonner et al., Cloning and Expressions of the Human and Rat m5 Muscarinic Acetylcholine Receptor Genes. Neuron 1:403-410 (1988).
Bonner et al., Identification of a Family of Muscarinic Acetylcholine Receptor Genes. Science 237:527-532 (1987).
Bossier et al., New derivatives of phenylisopropylamine: synthesis and anorexigenic activity. Chem. Abstr. 67:21527a (1967).
Bossier et al., Substituted benzylamines. Chem. Abstr. 66:46195h (1967).
Brauner-Osborne et al., Annulated Heterocyclic Bioisosteres of Norarecoline Synthesis and Molecular Pharmacology at Five Recombinant Human Muscarinic Acetylcholine Receptors. J. Med. Chem. 38:2188-2195 (1995).
Britton et al., The Use of 2-Pipecoline in the Mannich Reaction. J. Am. Pharm. Ass'n. 43:641-643 (1954).
Brown et al., Muscarinic Receptor Agonists and Antagonists. Goodman & Gilman's The Pharmcological Basis of Therapeutics 141-160 (McGraw-Hill 1996).
Burckhalter et al., Antiamebic Agents. V.1Promising Basic Amebicides Derived from 5-Chloro-8-quinolinol. J. Org. Chem. 26:4070-4076 (1961).
Burger et al., lodinated Dialkylaminoalkyl Pyridyl Ethers. J. Am. Chem. Soc. 68(3):520 (1946).
Burger et al., Tetrahydrofuryl Amino Alcohols. J. Am. Chem. Soc. 65(12):2382-2383 (1943).
Carr et al., Chemical Abstracts 94:156759 (1981).
Conde et al., Effects of Thiophene Analogues of Chloroamphetamines on Central Serotonergic Mechanisms. J. Med. Chem. 21:978-981 (1978).
Fleming, Chemical Abstracts 87:84839 (1977).
Foye et al., Heterocyclic analogs of Amphetamine: Thioureas, Dithiocarbamates, and Negatively Substituted Amides. J. Pharm. Sci. 68:591-595 (1979).
Fuller et al., Comparison of 4-Chloro-, 4-Bromo- and 4-Fluoroamphetamine in Rats: Drug Levels in Brain and Effects on Brain Serotonin Metabolism. Neuropharmacology 14:739-746 (1975).
Fuller et al., Effect of some lipid-soluble derivatives of amphetamine on amphetamine levels in rat brain. J. Pharm. Pharmacol. 25:828-829 (1973).
Fuller et al., Inhibition of PhenethanolaminesN-Methyl Transferase by Ring-Substitutedα-Methylphenethylamines (Amphetamines). J. Med. Chem. 14:322-325 (1971).
Glozman et al., Chemical Abstracts 71:61134(1969).
Hernestam et al., Chemical Abstracts 96:1105159 (1982).
Honkanen et al., Synthesis and Antihypertensive Activity of Some New Quinazoline Derivatives. J. Med. Chem. 26:1433-1438 (1983).
Iversen, Behavioural Evaluation of Cholinergic Drugs. Life Sciences 60(13/14):1145-1152 (1997).
Jaen et al., In Vitro Evaluation of the Subtype-Selective Muscarinic Agonist PD 1518832. Life Sciences 56(11/12):845-852 (1995).
Jones et al., Muscarinic Acetylcholine Receptors. Molecular Biology of G-Protein-Coupled Receptors 170-189 (Birkhauser Boston 1992).
Kaiser et al., Synthesis and Antimusccarinic Activity of Some 1-Cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and Related Compounds. J. Med. Chem. 36:610-616 (1993).
Kasa et al., The Cholinergic System in Alzheimer's Disease. Progress in Neurobiology 52:511-535 (1997).
Lafon, Chemical Abstracts 101:151764 (1984).
Law, B., Analysis of Basic Compounds on a Silica Column with an Aqueous Methanol Eluent; The Use of Quantitative Structure-Retention Relationships in Metabolite Identification. J. Cromatog. 407:1-18 (1987).
Levey, Allan I., Muscarinic Acetylcholine Receptor Expression in Memory Circuits: Implications for Treatment of Alzheimer Disease. Prox. Natl. Acad. Sci. USA 93:13541-13546 (1996).
Lukovits et al., Comparative Studies on Drug-Receptor Binding of Phenylethylamine Derivatives Using Calculated Group Contribution Constants. Int. J. Quantum Chem. 20:429-438 (1981).
McElvain et al., Piperidine Derivatives. XVII. Local anesthetics derived from substituted piperidinoalchols, 68:2592-2600 (1946).
Ono, Chemical Abstracts 88:105329 (1978).
Paris et al., N-aminomethylation en serie thiazolique: application a quelques amino-2 benzothiazoles. Bulletin de la Societe Chimique de France 2:672-673 (
Brann Mark
Currier Erika
Duggento Kate
Friberg Mikael
Messier Terri
Acadia Pharmaceuticals Inc.
Bernhardt Emily
Knobbe Martens Olson & Bear LLP
LandOfFree
Compounds with activity on muscarinic receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds with activity on muscarinic receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds with activity on muscarinic receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4135175